
    
      All participants will receive a single injection of Meningococcal (Groups A, C, Y and W-135)
      Polysaccharide Diphtheria Toxoid Conjugate vaccine on Day 0 and undergo immunogenicity
      assessment and safety monitoring post-vaccination.
    
  